COMMUNIQUÉS West-GlobeNewswire

Nancy J. Wysenski Joins Dova Pharmaceuticals’ Board of Directors

25/06/2018 - 13:00

DURHAM, N.C., June 25, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Nancy J. Wysenski will join Dova’s Board of Directors effective immediately. In addition to her board [...]

Kiniksa Pharmaceuticals, Ltd. Announces Exercise of the Underwriters’ Option to Purchase Additional Shares

25/06/2018 - 13:00

HAMILTON, Bermuda, June 25, 2018 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq:KNSA) (“Kiniksa”), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing [...]

Prodigy Health announces the launch of Prodigy Connect Real Time Inventory Management for High Value Specialty Pharmaceuticals

25/06/2018 - 11:00

AUSTIN, Texas, June 25, 2018 (GLOBE NEWSWIRE) -- Prodigy Health, a national specialty drug distributor that is leveraging innovative technology solutions for managing specialty pharmaceuticals in the hospital supply [...]

Veritas Appoints Mr. Filios Theodorou as Its Agent for Cyprus and SEMEA Countries

25/06/2018 - 09:15

VANCOUVER, British Columbia, June 25, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that Mr. Filios Theodorou has been appointed [...]

PledPharma establishes a Scientific Advisory Board for the continued clinical development of Aladote®

25/06/2018 - 08:35

PledPharma (publ) announces today that internationally leading experts will join a newly established Scientific Advisory Board to support the continued global clinical development of Aladote ® – a drug candidate being [...]

Solon Eiendom ASA : Primary insider notification

25/06/2018 - 08:31

(Oslo, Norway, June 22, 2018) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 25,000 shares in Solon Eiendom ASA at a price of NOK 29.31 per share. [...]

Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US

25/06/2018 - 08:30

Today PledPharma (publ) announces that the company has received a positive conclusion of the safety evaluation from the Data Safety Monitoring Board for the Aladote proof of principle study in patients with paracetamol [...]

CellCentric enters clinic with first-in-class p300/CBP inhibitor for late-stage prostate cancer

25/06/2018 - 08:00

CellCentric enters clinic with first-in-class p300/CBP inhibitor for late-stage prostate cancer Collaboration with world-leading prostate cancer researcher, Professor Johann de Bono of The Institute of Cancer Research, [...]

Kiadis Pharma to present at HollandBIO's Dutch Biotech Event 2018

25/06/2018 - 07:01

Kiadis Pharma to present at HollandBIO's Dutch Biotech Event 2018 Amsterdam, The Netherlands, June 25, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS ), a clinical [...]

MiniMed 670G System Real-World Data Show Improved Time in Range and Reduced Lows and Highs Across All Patient Groups Including a 41 Percent Time in Range Improvement for Previous MDI Patients

25/06/2018 - 01:49

DUBLIN - June 24, 2018 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 32,178 users of the MiniMed(TM) 670G system. Data on more than 2 million [...]

ERYTECH Confirms Strategic Focus of Eryaspase on Solid Tumors and Ceases Development in Acute Lymphoblastic Leukemia

24/06/2018 - 22:51

Conference call on Monday, June 25th at 2:30 pm CET/8:30 am EDT Focuses development efforts on solid tumor indications Confirms planned launch of company-sponsored randomized Phase 2 trial in first-line pancreatic [...]

ERYTECH confirme l’orientation stratégique d’eryaspase dans les tumeurs solides et interrompt ses développements dans la Leucémie Aiguë Lymphoblastique (LAL)

24/06/2018 - 22:51

Conférence téléphonique lundi 25 juin à 14h30 (heure de Paris) Concentration du développement sur les indications de tumeurs solides Confirmation du lancement d’un essai randomisé de Phase 2 dans le traitement de [...]

Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem1 Study Presented at ADA 2018 and Published in Diabetes Care

24/06/2018 - 22:01

Sotagliflozin, in Combination with Insulin, Decreased A1C Levels and Weight in Adults with Type 1 Diabetes THE WOODLANDS, Texas, June 24, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), today [...]

Phillips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards

24/06/2018 - 15:02

ARLINGTON, Va., June 24, 2018 (GLOBE NEWSWIRE) -- Today IMV, part of the Science and Medicine Group, and the leading market research and business intelligence provider to the Imaging industry, announced the category [...]

Lexicon Pharmaceuticals Announces Positive 52-Week Results From Sotagliflozin inTandem2 Study Presented at ADA 2018 and Published in Diabetes Care

23/06/2018 - 19:30

Sotagliflozin, in Combination with Insulin, Significantly Decreased A1C Levels and Reduced Weight at 52 Weeks Results Observed at 24 Weeks Persisted at 52 Weeks THE WOODLANDS, Texas, June 23, 2018 (GLOBE NEWSWIRE) -- [...]

Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial

23/06/2018 - 16:03

Orlando, US, 23 June 2018 - Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, according to [...]

Ozempic® provided greater weight reductions for adults with a baseline BMI of or above 25 kg/m2 than those with lower baseline BMI <25 kg/m2, in a SUSTAIN 7 post-hoc analysis

23/06/2018 - 16:02

Orlando, US, 23 June 2018 - Ozempic ® (semaglutide) 0.5 mg or 1.0 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with type 2 diabetes, regardless of baseline body mass [...]

Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA)

23/06/2018 - 16:02

Press Release - No. 17/2018 Zealand Pharma presents two dasiglucagon milestone studies at the 78th Scientific Sessions of the American Diabetes Association (ADA) Low doses of dasiglucagon effectively counteract low [...]

Tresiba® demonstrated significantly improved blood sugar control and lower rates of hypoglycaemia versus insulin glargine U300 in real-world evidence study

23/06/2018 - 16:01

Adults with type 2 diabetes treated with Tresiba ® (insulin degludec injection) had a significant reduction in HbA 1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Orlando, US, 23 June 2018 [...]